Euglena (8EG) 주식 개요유글레나는 일본에서 미세조류의 연구, 개발, 생산 및 판매에 종사하는 회사입니다. 자세히 보기8EG 펀더멘털 분석스노우플레이크 점수가치 평가4/6미래 성장3/6과거 실적0/6재무 건전성5/6배당0/6강점공정 가치 추정치보다 낮은 24.5% 에서 거래수익은 매년 52.28% 증가할 것으로 예상됩니다.지난 5년 동안 수입이 매년 22.2% 증가했습니다.위험 분석우리의 위험 점검에서 8EG에 대한 위험이 감지되지 않았습니다.모든 위험 점검 보기8EG Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW495,270 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG495,270 investors already sharing narrativesYour Fair Value€Current Price€1.7839.2% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-7b58b2016201920222025202620282031Revenue JP¥57.9bEarnings JP¥6.1bAdvancedSet Fair ValueView all narrativesEuglena Co., Ltd. 경쟁사BeiersdorfSymbol: XTRA:BEIMarket cap: €16.7bWeihai Baihe Biology TechnologicalSymbol: SHSE:603102Market cap: CN¥2.1bShinnihonseiyakuSymbol: TSE:4931Market cap: JP¥41.9bMicrobioSymbol: TPEX:4128Market cap: NT$10.1b가격 이력 및 성과Euglena 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가JP¥1.7852주 최고가JP¥2.9252주 최저가JP¥1.71베타-0.0891개월 변동-3.78%3개월 변동-21.24%1년 변동-23.93%3년 변동-67.93%5년 변동-78.16%IPO 이후 변동-68.65%최근 뉴스 및 업데이트Buy Or Sell Opportunity • Jun 15Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to €1.80. The fair value is estimated to be €2.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has grown by 66%.공시 • Jun 01Euglena Co., Ltd. to Report Q2, 2026 Results on Aug 07, 2026Euglena Co., Ltd. announced that they will report Q2, 2026 results on Aug 07, 2026Reported Earnings • May 20First quarter 2026 earnings released: JP¥0.23 loss per share (vs JP¥3.72 loss in 1Q 2025)First quarter 2026 results: JP¥0.23 loss per share (improved from JP¥3.72 loss in 1Q 2025). Revenue: JP¥13.2b (up 11% from 1Q 2025). Net loss: JP¥32.0m (loss narrowed 94% from 1Q 2025). Revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.공시 • Feb 16Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026.공시 • Dec 03Euglena Co., Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026Euglena Co., Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026공시 • Sep 03Euglena Co., Ltd. to Report Q3, 2025 Results on Nov 13, 2025Euglena Co., Ltd. announced that they will report Q3, 2025 results on Nov 13, 2025더 많은 업데이트 보기Recent updatesBuy Or Sell Opportunity • Jun 15Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to €1.80. The fair value is estimated to be €2.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has grown by 66%.공시 • Jun 01Euglena Co., Ltd. to Report Q2, 2026 Results on Aug 07, 2026Euglena Co., Ltd. announced that they will report Q2, 2026 results on Aug 07, 2026Reported Earnings • May 20First quarter 2026 earnings released: JP¥0.23 loss per share (vs JP¥3.72 loss in 1Q 2025)First quarter 2026 results: JP¥0.23 loss per share (improved from JP¥3.72 loss in 1Q 2025). Revenue: JP¥13.2b (up 11% from 1Q 2025). Net loss: JP¥32.0m (loss narrowed 94% from 1Q 2025). Revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.공시 • Feb 16Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026.공시 • Dec 03Euglena Co., Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026Euglena Co., Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026공시 • Sep 03Euglena Co., Ltd. to Report Q3, 2025 Results on Nov 13, 2025Euglena Co., Ltd. announced that they will report Q3, 2025 results on Nov 13, 2025공시 • Aug 19Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2025Euglena Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2025. For the year, the company expects net sales of JPY 50,000 million and operating profit of JPY 2,400 million.공시 • Jun 03Euglena Co., Ltd. to Report Q2, 2025 Results on Aug 08, 2025Euglena Co., Ltd. announced that they will report Q2, 2025 results on Aug 08, 2025공시 • Mar 01Euglena Co., Ltd. to Report Q1, 2025 Results on May 12, 2025Euglena Co., Ltd. announced that they will report Q1, 2025 results on May 12, 2025공시 • Feb 14Euglena Co., Ltd., Annual General Meeting, Mar 28, 2025Euglena Co., Ltd., Annual General Meeting, Mar 28, 2025.공시 • Dec 03Euglena Co., Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025Euglena Co., Ltd. announced that they will report fiscal year 2024 results on Feb 14, 2025Reported Earnings • Nov 13Third quarter 2024 earnings released: JP¥5.73 loss per share (vs JP¥2.98 loss in 3Q 2023)Third quarter 2024 results: JP¥5.73 loss per share (further deteriorated from JP¥2.98 loss in 3Q 2023). Revenue: JP¥11.6b (up 3.1% from 3Q 2023). Net loss: JP¥781.0m (loss widened 124% from 3Q 2023). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.공시 • Aug 27Euglena Co., Ltd. to Report Q3, 2024 Results on Nov 11, 2024Euglena Co., Ltd. announced that they will report Q3, 2024 results on Nov 11, 2024공시 • Aug 14Euglena Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2024Euglena Co., Ltd. revised consolidated earnings guidance for the year ended December 31, 2024. for the year, the company expects Net sales of JPY 48,000 million.New Risk • Aug 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding).공시 • Jun 02Euglena Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024Euglena Co., Ltd. announced that they will report Q2, 2024 results on Aug 08, 2024공시 • May 17Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2024Euglena Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2024. for the year, the company expects Net sales of JPY 52,500 million.Reported Earnings • May 16First quarter 2024 earnings released: EPS: JP¥1.48 (vs JP¥1.45 loss in 1Q 2023)First quarter 2024 results: EPS: JP¥1.48 (up from JP¥1.45 loss in 1Q 2023). Revenue: JP¥11.2b (up 2.9% from 1Q 2023). Net income: JP¥191.0m (up JP¥358.0m from 1Q 2023). Profit margin: 1.7% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.공시 • Mar 29Euglena Co., Ltd. to Report Q1, 2024 Results on May 13, 2024Euglena Co., Ltd. announced that they will report Q1, 2024 results on May 13, 2024Reported Earnings • Mar 26Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)Full year 2023 results: JP¥22.75 loss per share (improved from JP¥23.83 loss in FY 2022). Revenue: JP¥46.5b (up 4.7% from FY 2022). Net loss: JP¥2.65b (flat on FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.공시 • Feb 16Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024.Reported Earnings • Feb 16Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)Full year 2023 results: JP¥22.75 loss per share (improved from JP¥23.83 loss in FY 2022). Revenue: JP¥46.5b (up 4.7% from FY 2022). Net loss: JP¥2.65b (flat on FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.공시 • Jan 25Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million.Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million on January 24, 2024. As part of acquisition, 480 shares will be acquired for ¥0.75 million. The transaction is expected to complete on January 31, 2024.공시 • Jan 12Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd.Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd. on January 10, 2024.Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 3 highly experienced directors. Independent Outside Director Aiko Mochizuki was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Dec 05Euglena Co., Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024Euglena Co., Ltd. announced that they will report fiscal year 2023 results on Feb 14, 2024Reported Earnings • Nov 15Third quarter 2023 earnings released: JP¥2.98 loss per share (vs JP¥15.91 loss in 3Q 2022)Third quarter 2023 results: JP¥2.98 loss per share (improved from JP¥15.91 loss in 3Q 2022). Revenue: JP¥11.3b (down 6.5% from 3Q 2022). Net loss: JP¥349.0m (loss narrowed 81% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.공시 • Sep 02Euglena Co., Ltd. to Report Q3, 2023 Results on Nov 13, 2023Euglena Co., Ltd. announced that they will report Q3, 2023 results on Nov 13, 2023Reported Earnings • Aug 16Second quarter 2023 earnings releasedSecond quarter 2023 results: JP¥6.38 loss per share. Net loss: JP¥747.0m (flat on 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 5.1% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 6% per year.공시 • Jun 28Euglena Co., Ltd. to Report Q2, 2023 Results on Aug 14, 2023Euglena Co., Ltd. announced that they will report Q2, 2023 results on Aug 14, 2023Reported Earnings • May 17First quarter 2023 earnings releasedFirst quarter 2023 results: JP¥1.45 loss per share. Net loss: JP¥167.0m (flat on 1Q 2022). Revenue is forecast to grow 1.0% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 1% per year.Reported Earnings • Mar 31Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)Full year 2022 results: JP¥23.83 loss per share (improved from JP¥44.51 loss in FY 2021). Revenue: JP¥44.4b (up 46% from FY 2021). Net loss: JP¥2.67b (loss narrowed 43% from FY 2021). Revenue is forecast to stay flat during the next 3 years compared to a 4.8% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.공시 • Feb 16Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending Dec. 31, 2023Euglena Co., Ltd. provided consolidated earnings guidance for the fiscal year ending Dec. 31, 2023. The company expects net sales to be JPY 45,000 million.공시 • Feb 15Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023.Reported Earnings • Feb 14Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)Full year 2022 results: JP¥23.83 loss per share (improved from JP¥44.51 loss in FY 2021). Revenue: JP¥44.4b (up 46% from FY 2021). Net loss: JP¥2.67b (loss narrowed 43% from FY 2021). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.공시 • Feb 08Euglena Co., Ltd. announced that it has received ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd., Mazda Motor Corporation, Dai-ichi Life Holdings, Inc.On February 6, 2023, Euglena Co., Ltd. closed the transaction.공시 • Jan 20Euglena Co., Ltd. announced that it expects to receive ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd.Euglena Co., Ltd. announced that it will issue 3,208,500 common shares at a price of ¥935 for gross proceeds of ¥2,999,947,500 and 48 convertible bond-type bonds with stock acquisition rights at a price of ¥100,000,000 for gross proceeds of ¥4,800,000,000 for aggregate gross proceeds of ¥4,785,000,000 on January 19, 2023. The transaction will include participation from Marui Group Co., Ltd. of 2,139,000 shares and Rohto Pharmaceutical Co.,Ltd. of 1,069,500 shares post completion of the transaction. The company is issuing securities through third party allotment. The 10th stock acquisition rights are convertible into 5,133,689 shares. The transaction is expected to close on February 6, 2023. The transaction has been approved by the board of directors of the company.공시 • Dec 28Euglena Co., Ltd. to Report Fiscal Year 2022 Results on Feb 13, 2023Euglena Co., Ltd. announced that they will report fiscal year 2022 results on Feb 13, 2023공시 • Nov 17Euglena Co., Ltd. Provides Consolidated Financial Guidance for the Year Ending December 31, 2022Euglena Co., Ltd. provided consolidated financial guidance for the year ending December 31, 2022. For the year, the company expects net sales of JPY 44,000 million.공시 • Aug 16Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022Euglena Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2022. For the year, the company expects net sales of JPY 44,000 million.공시 • Jun 10Euglena Co., Ltd. to Report Q2, 2022 Results on Aug 10, 2022Euglena Co., Ltd. announced that they will report Q2, 2022 results on Aug 10, 2022공시 • May 18Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022Euglena Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2022. For the year, the company expects net sales of JPY 48,000 million.공시 • Apr 07Euglena Co., Ltd. to Report Q1, 2022 Results on May 13, 2022Euglena Co., Ltd. announced that they will report Q1, 2022 results on May 13, 2022Reported Earnings • Apr 02Full year 2021 earnings released: JP¥44.51 loss per share (vs JP¥17.15 loss in FY 2020)Full year 2021 results: JP¥44.51 loss per share (down from JP¥17.15 loss in FY 2020). Revenue: JP¥30.5b (up 118% from FY 2020). Net loss: JP¥4.68b (loss widened 194% from FY 2020). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.공시 • Feb 22Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022Euglena Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2022. For the year, the company expects net sales of JPY 48,000 million.공시 • Feb 12Euglena Co., Ltd., Annual General Meeting, Mar 26, 2022Euglena Co., Ltd., Annual General Meeting, Mar 26, 2022.Reported Earnings • Feb 11Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: JP¥44.51 loss per share (down from JP¥17.15 loss in FY 2020). Revenue: JP¥30.5b (up 118% from FY 2020). Net loss: JP¥4.68b (loss widened 194% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.공시 • Nov 27Euglena Co., Ltd. Provides Earnings Guidance for the Period from October 1, 2020 to December 31, 2021Euglena Co., Ltd. provided earnings guidance for the period from October 1, 2020 to December 31, 2021. For the period, the company expects net sales of ¥33,000 million.공시 • May 25Euglena Co., Ltd. Provides Consolidated Sales Guidance for the Full Year Ending September 30, 2021Euglena Co., Ltd. provided consolidated sales guidance for the full year ending September 30, 2021. For the year, the company expects net sales of JPY 22,000 million.Breakeven Date Change • May 17Forecast to breakeven in 2022The analyst covering Euglena expects the company to break even for the first time. New forecast suggests the company will make a profit of JP¥700.0m in 2022. Average annual earnings growth of 53% is required to achieve expected profit on schedule.Reported Earnings • May 17Second quarter 2021 earnings released: EPS JP¥1.75 (vs JP¥1.17 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥3.83b (up 34% from 2Q 2020). Net income: JP¥164.0m (up 51% from 2Q 2020). Profit margin: 4.3% (up from 3.8% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.공시 • Mar 16Euglena Co., Ltd., Chevron Lummus Global and Applied Research Associates, Inc. Announce Successful Production of Renewable Jet FuelEuglena Co., Ltd. (Euglena), Chevron Lummus Global (CLG) and Applied Research Associates, Inc. (ARA) are pleased to announce the successful production of renewable jet fuel from a blendstock of microalgae "euglena"-derived lipids, the first in the world to meet ASTM International D7566 Annex 6 standards. The recently produced renewable jet fuel was examined and certified to meet ASTM D7566 Annex 6 standards by a third-party analysis organization. ASTM standards are the most authoritative international fuel standards for aviation turbines produced from bio-based feedstocks. ASTM, the American Society for Testing and Materials, specify the means and testing methods for a wide variety of industrial materials.공시 • Mar 03Euglena Co., Ltd. to Report Q2, 2021 Results on May 14, 2021Euglena Co., Ltd. announced that they will report Q2, 2021 results on May 14, 2021Reported Earnings • Feb 18First quarter 2021 earnings released: JP¥3.87 loss per share (vs JP¥2.71 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: JP¥3.91b (up 22% from 1Q 2020). Net loss: JP¥360.0m (loss widened 43% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has remained flat, which means it is well ahead of earnings.Is New 90 Day High Low • Feb 08New 90-day high: €7.55The company is up 9.0% from its price of €6.95 on 10 November 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 7.0% over the same period.공시 • Jan 22Euglena Co., Ltd. (TSE:2931) entered into an agreement to acquire Liguna, K.K. from Noriko Minamizawa and Takeshi Matsumoto.Euglena Co., Ltd. (TSE:2931) entered into an agreement to acquire Liguna, K.K. from Noriko Minamizawa and Takeshi Matsumoto on January 21, 2021. Noriko Minamizawa will sell off 51.67% stake and Takeshi Matsumoto will sell 48.33% stake. Euglena Co., Ltd. will acquire 6000 shares of Liguna and the consideration will be paid in stock. Liguna, K.K. will operate as the wholly owned subsidiary of Euglena Co., Ltd. post completion of the transaction. For the year ending May 2020, Liguna reported net worth of ¥676 million, total assets of ¥1.51 billion, sales of ¥1.83 billion and operating income of ¥109 million. The transaction is subject to approval from shareholders of Liguna and is expected to complete on March 1, 2021.공시 • Jan 07Euglena Co., Ltd. to Report Q1, 2021 Results on Feb 15, 2021Euglena Co., Ltd. announced that they will report Q1, 2021 results on Feb 15, 2021Reported Earnings • Dec 26Full year 2020 earnings released: JP¥16.00 loss per shareThe company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: JP¥13.3b (down 4.7% from FY 2019). Net loss: JP¥1.49b (loss narrowed 85% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Dec 24New 90-day low: €6.05The company is down 20% from its price of €7.55 on 25 September 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period.Is New 90 Day High Low • Dec 02New 90-day low: €6.30The company is down 3.0% from its price of €6.50 on 03 September 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period.Reported Earnings • Nov 19Full year 2020 earnings released: JP¥16.00 loss per shareThe company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: JP¥13.3b (down 4.7% from FY 2019). Net loss: JP¥1.49b (loss narrowed 85% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.공시 • Nov 15Euglena Co., Ltd., Annual General Meeting, Dec 18, 2020Euglena Co., Ltd., Annual General Meeting, Dec 18, 2020.공시 • Oct 08Euglena Co., Ltd. to Report Fiscal Year 2020 Results on Nov 13, 2020Euglena Co., Ltd. announced that they will report fiscal year 2020 results on Nov 13, 2020공시 • Jul 30Euglena Co., Ltd. (TSE:2931) cancelled the acquisition of MEJ Inc. from Toru Koga and others.Euglena Co., Ltd. (TSE:2931) signed a share exchange contract to acquire MEJ Inc. from Toru Koga and others for approximately ¥670 million on May 8, 2019. Pursuant to the terms of the transaction Euglena Co., Ltd will issue 17 shares against one share of MEJ Inc. Euglena Co., Ltd will issue 0.9 million shares as consideration upon the delivery of MEJ Inc shares. Euglena Co., Ltd will acquire 51,850 outstanding shares of MEJ by share exchange, and make MEJ into a wholly owned subsidiary. MEJ Ltd reported total assets of ¥1.2 billion and net assets of ¥233 million as of September 30, 2018 and revenues of ¥721 million and operating profit of ¥57 million for the year ended September 30, 2018. The transaction is subject to approval by shareholders of MEJ in a meeting to be held on May 23, 2019. The transaction is resolved by the Board of Euglena Co., Ltd. The transaction is expected to complete on June 1, 2019. Plutus Consulting acted as third party appraiser and Miyake Imai Ikeda acted as legal advisor for Euglena Co., Ltd. Euglena Co., Ltd. (TSE:2931) cancelled the acquisition of MEJ Inc. from Toru Koga and others on May 8, 2020.주주 수익률8EGDE Personal ProductsDE 시장7D4.1%-0.4%3.8%1Y-23.9%-3.2%3.9%전체 주주 수익률 보기수익률 대 산업: 8EG은 지난 1년 동안 -3.2%의 수익을 기록한 German Personal Products 산업보다 저조한 성과를 냈습니다.수익률 대 시장: 8EG은 지난 1년 동안 3.9%를 기록한 German 시장보다 저조한 성과를 냈습니다.주가 변동성Is 8EG's price volatile compared to industry and market?8EG volatility8EG Average Weekly Movement4.6%Personal Products Industry Average Movement5.0%Market Average Movement5.6%10% most volatile stocks in DE Market12.5%10% least volatile stocks in DE Market2.7%안정적인 주가: 8EG는 지난 3개월 동안 German 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: 8EG의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트2005793Tomohiro Wakaharawww.euglena.jp유글레나 주식회사는 일본에서 미세조류의 연구, 개발, 생산 및 판매에 종사하고 있습니다. 또한 유글레나를 이용한 식품과 화장품을 제조 및 판매하고 있습니다. 또한 미세조류의 바이오 연료 기술 및 환경 관련 기술을 개발하고 생명공학 관련 사업에도 투자하고 있습니다.더 보기Euglena Co., Ltd. 기초 지표 요약Euglena의 순이익과 매출은 시가총액과 어떻게 비교됩니까?8EG 기초 통계시가총액€253.21m순이익 (TTM)-€1.79m매출 (TTM)€279.75m0.9x주가매출비율(P/S)-141.6x주가수익비율(P/E)8EG는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표8EG 손익계산서 (TTM)매출JP¥51.63b매출원가JP¥15.94b총이익JP¥35.69b기타 비용JP¥36.02b순이익-JP¥330.00m최근 보고된 실적Mar 31, 2026다음 실적 발표일Aug 07, 2026주당순이익(EPS)-2.37총이익률69.13%순이익률-0.64%부채/자본 비율82.5%8EG의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당0.6%현재 배당 수익률-83%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/05 13:17종가2026/07/03 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Euglena Co., Ltd.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Shima YamanakaSMBC NIKKO
Buy Or Sell Opportunity • Jun 15Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to €1.80. The fair value is estimated to be €2.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has grown by 66%.
공시 • Jun 01Euglena Co., Ltd. to Report Q2, 2026 Results on Aug 07, 2026Euglena Co., Ltd. announced that they will report Q2, 2026 results on Aug 07, 2026
Reported Earnings • May 20First quarter 2026 earnings released: JP¥0.23 loss per share (vs JP¥3.72 loss in 1Q 2025)First quarter 2026 results: JP¥0.23 loss per share (improved from JP¥3.72 loss in 1Q 2025). Revenue: JP¥13.2b (up 11% from 1Q 2025). Net loss: JP¥32.0m (loss narrowed 94% from 1Q 2025). Revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
공시 • Feb 16Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026.
공시 • Dec 03Euglena Co., Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026Euglena Co., Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026
공시 • Sep 03Euglena Co., Ltd. to Report Q3, 2025 Results on Nov 13, 2025Euglena Co., Ltd. announced that they will report Q3, 2025 results on Nov 13, 2025
Buy Or Sell Opportunity • Jun 15Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to €1.80. The fair value is estimated to be €2.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has grown by 66%.
공시 • Jun 01Euglena Co., Ltd. to Report Q2, 2026 Results on Aug 07, 2026Euglena Co., Ltd. announced that they will report Q2, 2026 results on Aug 07, 2026
Reported Earnings • May 20First quarter 2026 earnings released: JP¥0.23 loss per share (vs JP¥3.72 loss in 1Q 2025)First quarter 2026 results: JP¥0.23 loss per share (improved from JP¥3.72 loss in 1Q 2025). Revenue: JP¥13.2b (up 11% from 1Q 2025). Net loss: JP¥32.0m (loss narrowed 94% from 1Q 2025). Revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
공시 • Feb 16Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026.
공시 • Dec 03Euglena Co., Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026Euglena Co., Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026
공시 • Sep 03Euglena Co., Ltd. to Report Q3, 2025 Results on Nov 13, 2025Euglena Co., Ltd. announced that they will report Q3, 2025 results on Nov 13, 2025
공시 • Aug 19Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2025Euglena Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2025. For the year, the company expects net sales of JPY 50,000 million and operating profit of JPY 2,400 million.
공시 • Jun 03Euglena Co., Ltd. to Report Q2, 2025 Results on Aug 08, 2025Euglena Co., Ltd. announced that they will report Q2, 2025 results on Aug 08, 2025
공시 • Mar 01Euglena Co., Ltd. to Report Q1, 2025 Results on May 12, 2025Euglena Co., Ltd. announced that they will report Q1, 2025 results on May 12, 2025
공시 • Feb 14Euglena Co., Ltd., Annual General Meeting, Mar 28, 2025Euglena Co., Ltd., Annual General Meeting, Mar 28, 2025.
공시 • Dec 03Euglena Co., Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025Euglena Co., Ltd. announced that they will report fiscal year 2024 results on Feb 14, 2025
Reported Earnings • Nov 13Third quarter 2024 earnings released: JP¥5.73 loss per share (vs JP¥2.98 loss in 3Q 2023)Third quarter 2024 results: JP¥5.73 loss per share (further deteriorated from JP¥2.98 loss in 3Q 2023). Revenue: JP¥11.6b (up 3.1% from 3Q 2023). Net loss: JP¥781.0m (loss widened 124% from 3Q 2023). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
공시 • Aug 27Euglena Co., Ltd. to Report Q3, 2024 Results on Nov 11, 2024Euglena Co., Ltd. announced that they will report Q3, 2024 results on Nov 11, 2024
공시 • Aug 14Euglena Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2024Euglena Co., Ltd. revised consolidated earnings guidance for the year ended December 31, 2024. for the year, the company expects Net sales of JPY 48,000 million.
New Risk • Aug 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding).
공시 • Jun 02Euglena Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024Euglena Co., Ltd. announced that they will report Q2, 2024 results on Aug 08, 2024
공시 • May 17Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2024Euglena Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2024. for the year, the company expects Net sales of JPY 52,500 million.
Reported Earnings • May 16First quarter 2024 earnings released: EPS: JP¥1.48 (vs JP¥1.45 loss in 1Q 2023)First quarter 2024 results: EPS: JP¥1.48 (up from JP¥1.45 loss in 1Q 2023). Revenue: JP¥11.2b (up 2.9% from 1Q 2023). Net income: JP¥191.0m (up JP¥358.0m from 1Q 2023). Profit margin: 1.7% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.
공시 • Mar 29Euglena Co., Ltd. to Report Q1, 2024 Results on May 13, 2024Euglena Co., Ltd. announced that they will report Q1, 2024 results on May 13, 2024
Reported Earnings • Mar 26Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)Full year 2023 results: JP¥22.75 loss per share (improved from JP¥23.83 loss in FY 2022). Revenue: JP¥46.5b (up 4.7% from FY 2022). Net loss: JP¥2.65b (flat on FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.
공시 • Feb 16Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024.
Reported Earnings • Feb 16Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)Full year 2023 results: JP¥22.75 loss per share (improved from JP¥23.83 loss in FY 2022). Revenue: JP¥46.5b (up 4.7% from FY 2022). Net loss: JP¥2.65b (flat on FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.
공시 • Jan 25Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million.Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million on January 24, 2024. As part of acquisition, 480 shares will be acquired for ¥0.75 million. The transaction is expected to complete on January 31, 2024.
공시 • Jan 12Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd.Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd. on January 10, 2024.
Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 3 highly experienced directors. Independent Outside Director Aiko Mochizuki was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Dec 05Euglena Co., Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024Euglena Co., Ltd. announced that they will report fiscal year 2023 results on Feb 14, 2024
Reported Earnings • Nov 15Third quarter 2023 earnings released: JP¥2.98 loss per share (vs JP¥15.91 loss in 3Q 2022)Third quarter 2023 results: JP¥2.98 loss per share (improved from JP¥15.91 loss in 3Q 2022). Revenue: JP¥11.3b (down 6.5% from 3Q 2022). Net loss: JP¥349.0m (loss narrowed 81% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
공시 • Sep 02Euglena Co., Ltd. to Report Q3, 2023 Results on Nov 13, 2023Euglena Co., Ltd. announced that they will report Q3, 2023 results on Nov 13, 2023
Reported Earnings • Aug 16Second quarter 2023 earnings releasedSecond quarter 2023 results: JP¥6.38 loss per share. Net loss: JP¥747.0m (flat on 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 5.1% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 6% per year.
공시 • Jun 28Euglena Co., Ltd. to Report Q2, 2023 Results on Aug 14, 2023Euglena Co., Ltd. announced that they will report Q2, 2023 results on Aug 14, 2023
Reported Earnings • May 17First quarter 2023 earnings releasedFirst quarter 2023 results: JP¥1.45 loss per share. Net loss: JP¥167.0m (flat on 1Q 2022). Revenue is forecast to grow 1.0% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 1% per year.
Reported Earnings • Mar 31Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)Full year 2022 results: JP¥23.83 loss per share (improved from JP¥44.51 loss in FY 2021). Revenue: JP¥44.4b (up 46% from FY 2021). Net loss: JP¥2.67b (loss narrowed 43% from FY 2021). Revenue is forecast to stay flat during the next 3 years compared to a 4.8% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
공시 • Feb 16Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending Dec. 31, 2023Euglena Co., Ltd. provided consolidated earnings guidance for the fiscal year ending Dec. 31, 2023. The company expects net sales to be JPY 45,000 million.
공시 • Feb 15Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023.
Reported Earnings • Feb 14Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)Full year 2022 results: JP¥23.83 loss per share (improved from JP¥44.51 loss in FY 2021). Revenue: JP¥44.4b (up 46% from FY 2021). Net loss: JP¥2.67b (loss narrowed 43% from FY 2021). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
공시 • Feb 08Euglena Co., Ltd. announced that it has received ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd., Mazda Motor Corporation, Dai-ichi Life Holdings, Inc.On February 6, 2023, Euglena Co., Ltd. closed the transaction.
공시 • Jan 20Euglena Co., Ltd. announced that it expects to receive ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd.Euglena Co., Ltd. announced that it will issue 3,208,500 common shares at a price of ¥935 for gross proceeds of ¥2,999,947,500 and 48 convertible bond-type bonds with stock acquisition rights at a price of ¥100,000,000 for gross proceeds of ¥4,800,000,000 for aggregate gross proceeds of ¥4,785,000,000 on January 19, 2023. The transaction will include participation from Marui Group Co., Ltd. of 2,139,000 shares and Rohto Pharmaceutical Co.,Ltd. of 1,069,500 shares post completion of the transaction. The company is issuing securities through third party allotment. The 10th stock acquisition rights are convertible into 5,133,689 shares. The transaction is expected to close on February 6, 2023. The transaction has been approved by the board of directors of the company.
공시 • Dec 28Euglena Co., Ltd. to Report Fiscal Year 2022 Results on Feb 13, 2023Euglena Co., Ltd. announced that they will report fiscal year 2022 results on Feb 13, 2023
공시 • Nov 17Euglena Co., Ltd. Provides Consolidated Financial Guidance for the Year Ending December 31, 2022Euglena Co., Ltd. provided consolidated financial guidance for the year ending December 31, 2022. For the year, the company expects net sales of JPY 44,000 million.
공시 • Aug 16Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022Euglena Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2022. For the year, the company expects net sales of JPY 44,000 million.
공시 • Jun 10Euglena Co., Ltd. to Report Q2, 2022 Results on Aug 10, 2022Euglena Co., Ltd. announced that they will report Q2, 2022 results on Aug 10, 2022
공시 • May 18Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022Euglena Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2022. For the year, the company expects net sales of JPY 48,000 million.
공시 • Apr 07Euglena Co., Ltd. to Report Q1, 2022 Results on May 13, 2022Euglena Co., Ltd. announced that they will report Q1, 2022 results on May 13, 2022
Reported Earnings • Apr 02Full year 2021 earnings released: JP¥44.51 loss per share (vs JP¥17.15 loss in FY 2020)Full year 2021 results: JP¥44.51 loss per share (down from JP¥17.15 loss in FY 2020). Revenue: JP¥30.5b (up 118% from FY 2020). Net loss: JP¥4.68b (loss widened 194% from FY 2020). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
공시 • Feb 22Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022Euglena Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2022. For the year, the company expects net sales of JPY 48,000 million.
공시 • Feb 12Euglena Co., Ltd., Annual General Meeting, Mar 26, 2022Euglena Co., Ltd., Annual General Meeting, Mar 26, 2022.
Reported Earnings • Feb 11Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: JP¥44.51 loss per share (down from JP¥17.15 loss in FY 2020). Revenue: JP¥30.5b (up 118% from FY 2020). Net loss: JP¥4.68b (loss widened 194% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
공시 • Nov 27Euglena Co., Ltd. Provides Earnings Guidance for the Period from October 1, 2020 to December 31, 2021Euglena Co., Ltd. provided earnings guidance for the period from October 1, 2020 to December 31, 2021. For the period, the company expects net sales of ¥33,000 million.
공시 • May 25Euglena Co., Ltd. Provides Consolidated Sales Guidance for the Full Year Ending September 30, 2021Euglena Co., Ltd. provided consolidated sales guidance for the full year ending September 30, 2021. For the year, the company expects net sales of JPY 22,000 million.
Breakeven Date Change • May 17Forecast to breakeven in 2022The analyst covering Euglena expects the company to break even for the first time. New forecast suggests the company will make a profit of JP¥700.0m in 2022. Average annual earnings growth of 53% is required to achieve expected profit on schedule.
Reported Earnings • May 17Second quarter 2021 earnings released: EPS JP¥1.75 (vs JP¥1.17 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥3.83b (up 34% from 2Q 2020). Net income: JP¥164.0m (up 51% from 2Q 2020). Profit margin: 4.3% (up from 3.8% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
공시 • Mar 16Euglena Co., Ltd., Chevron Lummus Global and Applied Research Associates, Inc. Announce Successful Production of Renewable Jet FuelEuglena Co., Ltd. (Euglena), Chevron Lummus Global (CLG) and Applied Research Associates, Inc. (ARA) are pleased to announce the successful production of renewable jet fuel from a blendstock of microalgae "euglena"-derived lipids, the first in the world to meet ASTM International D7566 Annex 6 standards. The recently produced renewable jet fuel was examined and certified to meet ASTM D7566 Annex 6 standards by a third-party analysis organization. ASTM standards are the most authoritative international fuel standards for aviation turbines produced from bio-based feedstocks. ASTM, the American Society for Testing and Materials, specify the means and testing methods for a wide variety of industrial materials.
공시 • Mar 03Euglena Co., Ltd. to Report Q2, 2021 Results on May 14, 2021Euglena Co., Ltd. announced that they will report Q2, 2021 results on May 14, 2021
Reported Earnings • Feb 18First quarter 2021 earnings released: JP¥3.87 loss per share (vs JP¥2.71 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: JP¥3.91b (up 22% from 1Q 2020). Net loss: JP¥360.0m (loss widened 43% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
Is New 90 Day High Low • Feb 08New 90-day high: €7.55The company is up 9.0% from its price of €6.95 on 10 November 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 7.0% over the same period.
공시 • Jan 22Euglena Co., Ltd. (TSE:2931) entered into an agreement to acquire Liguna, K.K. from Noriko Minamizawa and Takeshi Matsumoto.Euglena Co., Ltd. (TSE:2931) entered into an agreement to acquire Liguna, K.K. from Noriko Minamizawa and Takeshi Matsumoto on January 21, 2021. Noriko Minamizawa will sell off 51.67% stake and Takeshi Matsumoto will sell 48.33% stake. Euglena Co., Ltd. will acquire 6000 shares of Liguna and the consideration will be paid in stock. Liguna, K.K. will operate as the wholly owned subsidiary of Euglena Co., Ltd. post completion of the transaction. For the year ending May 2020, Liguna reported net worth of ¥676 million, total assets of ¥1.51 billion, sales of ¥1.83 billion and operating income of ¥109 million. The transaction is subject to approval from shareholders of Liguna and is expected to complete on March 1, 2021.
공시 • Jan 07Euglena Co., Ltd. to Report Q1, 2021 Results on Feb 15, 2021Euglena Co., Ltd. announced that they will report Q1, 2021 results on Feb 15, 2021
Reported Earnings • Dec 26Full year 2020 earnings released: JP¥16.00 loss per shareThe company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: JP¥13.3b (down 4.7% from FY 2019). Net loss: JP¥1.49b (loss narrowed 85% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Dec 24New 90-day low: €6.05The company is down 20% from its price of €7.55 on 25 September 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Dec 02New 90-day low: €6.30The company is down 3.0% from its price of €6.50 on 03 September 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period.
Reported Earnings • Nov 19Full year 2020 earnings released: JP¥16.00 loss per shareThe company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: JP¥13.3b (down 4.7% from FY 2019). Net loss: JP¥1.49b (loss narrowed 85% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
공시 • Nov 15Euglena Co., Ltd., Annual General Meeting, Dec 18, 2020Euglena Co., Ltd., Annual General Meeting, Dec 18, 2020.
공시 • Oct 08Euglena Co., Ltd. to Report Fiscal Year 2020 Results on Nov 13, 2020Euglena Co., Ltd. announced that they will report fiscal year 2020 results on Nov 13, 2020
공시 • Jul 30Euglena Co., Ltd. (TSE:2931) cancelled the acquisition of MEJ Inc. from Toru Koga and others.Euglena Co., Ltd. (TSE:2931) signed a share exchange contract to acquire MEJ Inc. from Toru Koga and others for approximately ¥670 million on May 8, 2019. Pursuant to the terms of the transaction Euglena Co., Ltd will issue 17 shares against one share of MEJ Inc. Euglena Co., Ltd will issue 0.9 million shares as consideration upon the delivery of MEJ Inc shares. Euglena Co., Ltd will acquire 51,850 outstanding shares of MEJ by share exchange, and make MEJ into a wholly owned subsidiary. MEJ Ltd reported total assets of ¥1.2 billion and net assets of ¥233 million as of September 30, 2018 and revenues of ¥721 million and operating profit of ¥57 million for the year ended September 30, 2018. The transaction is subject to approval by shareholders of MEJ in a meeting to be held on May 23, 2019. The transaction is resolved by the Board of Euglena Co., Ltd. The transaction is expected to complete on June 1, 2019. Plutus Consulting acted as third party appraiser and Miyake Imai Ikeda acted as legal advisor for Euglena Co., Ltd. Euglena Co., Ltd. (TSE:2931) cancelled the acquisition of MEJ Inc. from Toru Koga and others on May 8, 2020.
